Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in Interest ReceivablesFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Marker Therapeutics (MRKR) Share-based Compensation (2016 - 2025)

Historic Share-based Compensation for Marker Therapeutics (MRKR) over the last 11 years, with Q3 2025 value amounting to $33000.0.

  • Marker Therapeutics' Share-based Compensation fell 3773.58% to $33000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $476824.0, marking a year-over-year increase of 4089.84%. This contributed to the annual value of $246000.0 for FY2024, which is 8445.99% down from last year.
  • As of Q3 2025, Marker Therapeutics' Share-based Compensation stood at $33000.0, which was down 3773.58% from $14000.0 recorded in Q2 2025.
  • Marker Therapeutics' Share-based Compensation's 5-year high stood at $1.7 million during Q2 2021, with a 5-year trough of $14000.0 in Q2 2025.
  • For the 5-year period, Marker Therapeutics' Share-based Compensation averaged around $714009.6, with its median value being $606000.0 (2023).
  • Per our database at Business Quant, Marker Therapeutics' Share-based Compensation plummeted by 8960.4% in 2024 and then skyrocketed by 37740.91% in 2025.
  • Over the past 5 years, Marker Therapeutics' Share-based Compensation (Quarter) stood at $1.5 million in 2021, then tumbled by 51.12% to $717000.0 in 2022, then tumbled by 80.06% to $143000.0 in 2023, then plummeted by 64.56% to $50680.0 in 2024, then crashed by 34.89% to $33000.0 in 2025.
  • Its Share-based Compensation stands at $33000.0 for Q3 2025, versus $14000.0 for Q2 2025 and $379144.0 for Q1 2025.